Home/Pipeline/TR-45

TR-45

Rheumatoid Arthritis

Pre-clinicalActive

Key Facts

Indication

Rheumatoid Arthritis

Phase

Pre-clinical

Status

Active

Company

Theripion

About Theripion

Theripion is a preclinical-stage biotechnology company founded in 2018 and based in Cambridge, USA, with a stated secondary location in Seattle. The company has developed a proprietary Paraoxonase Fusion Protein Platform to create bifunctional therapeutics aimed at diseases involving oxidative stress, inflammation, and dysfunctional lipid metabolism. With a leadership team possessing decades of combined industry experience, Theripion is seeking partnerships and funding to advance its lead candidates, including TR-43 and Ther4, into clinical trials. The company's core value proposition is rescuing patients from conditions like cardiovascular disease, rheumatoid arthritis, and neurodegenerative disorders.

View full company profile

Therapeutic Areas

Cardiovascular Disease Autoimmune Diseases Neurodegenerative Diseases Inflammatory Diseases Metabolic Disease

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active